Bristol-Myers Squibb competitorsClear all

Daiichi Sankyo's top competitors include Regeneron Pharmaceuticals, Gilead Sciences, Edwards Lifesciences, Lonza, Catalent, Pfizer, Johnson & Johnson, AbbVie, Merck Group, AstraZeneca and Eli Lilly.
Daiichi Sankyo
Daiichi Sankyo
Daiichi Sankyo is a developer of pharmaceutical products.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
Gilead Sciences
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences is a company operating as a global provider of patient-focused medical solutions for structural heart disease and critical care monitoring.
Lonza
Lonza
Lonza (also known as Lonza Biologics) is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries.
Catalent
Catalent
Catalent Pharma Solutions is a company providing integrated services, drug delivery technologies, and manufacturing solutions.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field.
AbbVie
AbbVie
AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Merck Group
Merck Group
Merck Group is a pharmaceutical, chemical, and life sciences company.
AstraZeneca
AstraZeneca
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
Eli Lilly
Eli Lilly
Eli Lilly and Company is a company that discovers, develops, manufactures, and markets pharmaceutical products.
Founding Date
Founding Date
2005
Founding Date
1988
Founding Date
1987
Founding Date
1958
Founding Date
1897
Founding Date
2007
Founding Date
1849
Founding Date
1886
Founding Date
2013
Founding Date
1668
Founding Date
1999
Founding Date
1876
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Chuo City, JP HQ
Wien, AT
Braine L'alleud, BE
São Paulo, BR
Beijing, CN
Shanghai, CN
Shanghai, CN
see more
Locations
Tarrytown, US HQ
Dublin, IE
Limerick, IE
Uxbridge, GB
Bernards, US
Rensselaer, US
Sleepy Hollow, US
see more
Locations
Foster City, US HQ
Abb, AR
Melbourne, AU
Wien, AT
Machelen, BE
São Paulo, BR
Edmonton, CA
see more
Locations
Irvine, US HQ
Macquarie Park, AU
Wien, AT
Dilbeek, BE
Mississauga, CA
Shanghai, CN
see more
Locations
Basel, CH HQ
Ingeniero Maschwitz, AR
Bella Vista, AU
Brooklyn, AU
Derrimut, AU
Mount Waverley, AU
Trentham, AU
see more
Locations
Franklin Township, US HQ
Loma Hermosa, AR
Bruxelles, BE
Charleroi, BE
Charleroi, BE
Indaiatuba, BR
Sorocaba, BR
see more
Locations
New York, US HQ
Buenos Aires, AR
Villa Adelina, AR
Bentley, AU
Melbourne, AU
Mulgrave, AU
Sydney, AU
see more
Locations
New Brunswick, US HQ
Buenos Aires, AR
Chippendale, AU
Wien, AT
Minsk, BY
Beerse, BE
Brussel, BE
see more
Locations
Lake Bluff, US HQ
Alger, DZ
Buenos Aires, AR
Mascot, AU
Wien, AT
Wavre, BE
Sarajevo, BA
see more
Locations
Darmstadt, DE HQ
Hydra, DZ
Csd, AR
Bayswater, AU
Bayswater, AU
Macquarie Park, AU
Wien, AT
see more
Locations
Cambridge, GB HQ
Alger, DZ
Buenos Aires, AR
Haedo, AR
Macquarie Park, AU
Macquarie Park, AU
North Ryde, AU
see more
Locations
Indianapolis, US HQ
Melrose Park, AU
Wien, AT
Brussel, BE
São Paulo, BR
Toronto, CA
Las Condes, CL
see more
Employees
Employees
N/A
Employees
8,1009% increase
Employees
11,8007% increase
Employees
13,9009% increase
Employees
16,5404% increase
Employees
13,90013% increase
Employees
88,3004% decrease
Employees
132,2002% decrease
Employees
29,1601% decrease
Employees
58,1272% increase
Employees
70,6009% increase
Employees
33,62513% decrease
Valuation ($)
Valuation ($)
49.7 b
Valuation ($)
52.9 b
Valuation ($)
83.8 b
Valuation ($)
57.3 b
Valuation ($)
N/A
Valuation ($)
18.3 b
Valuation ($)
220.8 b
Valuation ($)
443.7 b
Valuation ($)
204.3 b
Valuation ($)
75.1 b
Valuation ($)
142.2 b
Valuation ($)
187.5 b
Twitter followers
Twitter followers
558
Twitter followers
28.1 k
Twitter followers
67.6 k
Twitter followers
9.1 k
Twitter followers
7 k
Twitter followers
18.9 k
Twitter followers
25.4 k
Twitter followers
231.3 k
Twitter followers
70.5 k
Twitter followers
20.7 k
Twitter followers
267.8 k
Twitter followers
130.8 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
31
Number of tweets (last 30 days)
14
Number of tweets (last 30 days)
18
Number of tweets (last 30 days)
5
Number of tweets (last 30 days)
139
Number of tweets (last 30 days)
6
Number of tweets (last 30 days)
81
Number of tweets (last 30 days)
28
Number of tweets (last 30 days)
92
Number of tweets (last 30 days)
39
Number of tweets (last 30 days)
93
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
15.5
Average likes per tweet (last 30 days)
91.8
Average likes per tweet (last 30 days)
4.7
Average likes per tweet (last 30 days)
4
Average likes per tweet (last 30 days)
2
Average likes per tweet (last 30 days)
12.2
Average likes per tweet (last 30 days)
9.9
Average likes per tweet (last 30 days)
9.5
Average likes per tweet (last 30 days)
5.2
Average likes per tweet (last 30 days)
58.8
Average likes per tweet (last 30 days)
5.6
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
64.03%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
43.21%
Percentage of tweets with engagement (last 30 days)
89.29%
Percentage of tweets with engagement (last 30 days)
89.13%
Percentage of tweets with engagement (last 30 days)
92.31%
Percentage of tweets with engagement (last 30 days)
61.29%
Alexa Website Rank
Alexa Website Rank
240801
Alexa Website Rank
N/A
Alexa Website Rank
112610
Alexa Website Rank
252663
Alexa Website Rank
199696
Alexa Website Rank
335605
Alexa Website Rank
28407
Alexa Website Rank
19571
Alexa Website Rank
96656
Alexa Website Rank
150790
Alexa Website Rank
57766
Alexa Website Rank
108463
Employee Rating
Employee Rating
N/A
Employee Rating
4
Employee Rating
3.8
Employee Rating
4
Employee Rating
3.4
Employee Rating
3.5
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4
Employee Rating
4
Employee Rating
4.2
Employee Rating
4

Financial

Revenue (est.)
Revenue (est.)
¥981.8b (FY, 2019)
Revenue (est.)
$8.5b (FY, 2020)
Revenue (est.)
$24.7b (FY, 2020)
Revenue (est.)
$4.4b (FY, 2020)
Revenue (est.)
CHF4.5b (FY, 2020)
Revenue (est.)
$3.1b (FY, 2020)
Revenue (est.)
$41.9b (FY, 2020)
Revenue (est.)
$82.1b (FY, 2019)
Revenue (est.)
$45.8b (FY, 2020)
Revenue (est.)
€17.5b (FY, 2020)
Revenue (est.)
$24.4b (FY, 2019)
Revenue (est.)
$24.5b (FY, 2020)
Cost of goods
Cost of goods
¥343.2b (FY, 2019)
Cost of goods
N/A
Cost of goods
$4.6b (FY, 2020)
Cost of goods
$1.1b (FY, 2020)
Cost of goods
CHF2.7b (FY, 2020)
Cost of goods
$2.1b (FY, 2020)
Cost of goods
$8.7b (FY, 2020)
Cost of goods
$27.6b (FY, 2019)
Cost of goods
$15.4b (FY, 2020)
Cost of goods
€6.8b (FY, 2020)
Cost of goods
$4.9b (FY, 2019)
Cost of goods
$5.5b (FY, 2020)
Gross profit
Gross profit
¥638.6b (FY, 2019)
Gross profit
N/A
Gross profit
$20.1b (FY, 2020)
Gross profit
$3.3b (FY, 2020)
Gross profit
CHF1.8b (FY, 2020)
Gross profit
$983.3m (FY, 2020)
Gross profit
$33.2b (FY, 2020)
Gross profit
$54.5b (FY, 2019)
Gross profit
$30.4b (FY, 2020)
Gross profit
€10.7b (FY, 2020)
Gross profit
$19.5b (FY, 2019)
Gross profit
$19.1b (FY, 2020)
Net income
Net income
¥129b (FY, 2019)
Net income
$3.5b (FY, 2020)
Net income
$89m (FY, 2020)
Net income
$823.4m (FY, 2020)
Net income
CHF871m (FY, 2020)
Net income
$220.7m (FY, 2020)
Net income
$9.7b (FY, 2020)
Net income
$15.1b (FY, 2019)
Net income
$4.6b (FY, 2020)
Net income
€2b (FY, 2020)
Net income
$1.2b (FY, 2019)
Net income
$6.2b (FY, 2020)

Operating

Countries
Countries
N/A
Countries
N/A
Countries
35 (FY, 2019)
Countries
N/A
Countries
30 (FY, 2019)
Countries
85 (FY, 2020)
Countries
125 (FY, 2019)
Countries
60 (FY, 2018)
Countries
175 (FY, 2019)
Countries
66 (FY, 2020)
Countries
100 (FY, 2020)
Countries
120 (FY, 2019)
Manufacturing Facilities
Manufacturing Facilities
13 (Dec, 2020)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
7 (FY, 2019)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
97 (FY, 2019)
Manufacturing Facilities
14 (FY, 2019)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing and R&D Facilities
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
55 (FY, 2019)
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
14 (FY, 2018)
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
N/A
Manufacturing and R&D Facilities
N/A
Patents (US)
Patents (US)
N/A
Patents (US)
21 (FY, 2019)
Patents (US)
650 (Dec, 2020)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents and Patent Applications
Patents and Patent Applications
N/A
Patents and Patent Applications
N/A
Patents and Patent Applications
N/A
Patents and Patent Applications
4.7 k (FY, 2019)
Patents and Patent Applications
N/A
Patents and Patent Applications
1.3 k (FY, 2020)
Patents and Patent Applications
N/A
Patents and Patent Applications
N/A
Patents and Patent Applications
N/A
Patents and Patent Applications
N/A
Patents and Patent Applications
N/A
Patents and Patent Applications
N/A
Patients Included in Clinical Trials
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
104 k (FY, 2018)
Patients Included in Clinical Trials
N/A
Patients Included in Clinical Trials
33 k (FY, 2017)
Patients Included in Clinical Trials
N/A
Phase I Trials Products
Phase I Trials Products
16 (FY, 2019)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
26 (FY, 2019)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
27 (FY, 2019)
Phase I Trials Products (Oncology)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
7 (FY, 2019)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
18 (Mar, 2020)
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Oncology)
N/A
Phase I Trials Products (Other)
Phase I Trials Products (Other)
2 (Aug, 2020)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
1 (Mar, 2020)
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase I Trials Products (Other)
N/A
Phase II Trials Products
Phase II Trials Products
7 (FY, 2019)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
37 (FY, 2019)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
9 (FY, 2019)
Phase II Trials Products (Oncology)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
2 (FY, 2019)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
3 (Mar, 2020)
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Oncology)
N/A
Phase II Trials Products (Other)
Phase II Trials Products (Other)
1 (Aug, 2020)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
1 (FY, 2018)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
2 (Mar, 2020)
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase II Trials Products (Other)
N/A
Phase III Trials Products
Phase III Trials Products
7 (FY, 2019)
Phase III Trials Products
N/A
Phase III Trials Products
27 (FY, 2019)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
23 (FY, 2019)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
15 (FY, 2019)
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
1 (FY, 2019)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
13 (Mar, 2020)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Products
Products
N/A
Products
7 (FY, 2019)
Products
24 (FY, 2019)
Products
N/A
Products
N/A
Products
7 k (FY, 2020)
Products
N/A
Products
N/A
Products
N/A
Products
300 k (FY, 2020)
Products
N/A
Products
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
171 (FY, 2020)
Projects in R&D Pipeline
66 (FY, 2016)
Suppliers
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
3.5 k (Jun, 2018)
Suppliers
51 k (FY, 2018)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Trademarks
Trademarks
116 (Dec, 2020)
Trademarks
13 (FY, 2019)
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A
Trademarks
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 8.9m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 1b
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Regeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
8,100↑ 9% increase

Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.

View company
Gilead Sciences
HQ
Foster City, US
Employees
11,800↑ 7% increase

Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

View company
Edwards Lifesciences
HQ
Irvine, US
Employees
13,900↑ 9% increase

Edwards Lifesciences is a company operating as a global provider of patient-focused medical solutions for structural heart disease and critical care monitoring.

View company
Lonza
HQ
Basel, CH
Employees
16,540↑ 4% increase

Lonza (also known as Lonza Biologics) is a company that supplies active ingredients, chemical intermediates, and biotechnology solutions to the pharmaceutical and agrochemical industries.

View company